The authors provide evidence that the selected Src/c-Abl kinases inhibitor bosutinib (DrugBank Accession Number DB06616, which is approved for chronic myelogenous leukaemia) promoted autophagy and rescued ALS patient motor neurons from degeneration [67], whereas in an innovative 3D model of human ALS motor unit its co-application significantly increased the beneficial effects of rapamycin towards muscle contraction deficit [68]. The gene discussed is SRC; the disease is amyotrophic lateral sclerosis.